Compare · MDLN vs SGP
MDLN vs SGP
Side-by-side comparison of Medline Inc. (MDLN) and SpyGlass Pharma Inc. (SGP): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDLN and SGP operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $51.52B, about 47.8x SGP ($1.08B).
- MDLN has been more active in the news (13 items in the past 4 weeks vs 4 for SGP).
- MDLN has more recent analyst coverage (25 ratings vs 6 for SGP).
- Company
- Medline Inc.
- SpyGlass Pharma Inc.
- Price
- -
- -
- Market cap
- $51.52B
- $1.08B
- 1M return
- +8.89%
- -
- 1Y return
- -3.93%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- 2026
- News (4w)
- 13
- 4
- Recent ratings
- 25
- 6
Latest MDLN
- Chief Legal Officer Liberman Alexander M. was granted 798,680 units of Class B Common Stock, increasing direct ownership by 352% to 1,025,603 units (SEC Form 4)
- Chief Product Officer Laabs Amanda H. was granted 520,127 units of Class B Common Stock, increasing direct ownership by 207% to 771,197 units (SEC Form 4)
- Chief Commercial Officer Golwas Douglas P was granted 895,512 units of Class B Common Stock, increasing direct ownership by 164% to 967,560 units (SEC Form 4)
- Chief Executive Officer Boyle James M was granted 2,516,260 units of Class B Common Stock, increasing direct ownership by 7,591% to 1,869,921 units (SEC Form 4)
- Medline Inc. announces launch of secondary offering of Class A common stock
- SEC Form S-1 filed by Medline Inc.
- SEC Form SCHEDULE 13G filed by Medline Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Medline Inc.
- SEC Form 10-Q filed by Medline Inc.
- Medline Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest SGP
- SEC Form 10-Q filed by SpyGlass Pharma Inc.
- SpyGlass Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
- SpyGlass Pharma Reports Third Quarter 2026 Financial Results and Provides Corporate Updates
- SpyGlass Pharma to Participate in Upcoming Investor Conferences
- SEC Form 8-K filed by SpyGlass Pharma Inc.
- SpyGlass Pharma Announces Positive 4-Year Data From First-in-Human Trial of Its Innovative BIM-IOL System
- SpyGlass Pharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- SpyGlass Pharma Acquires Advanced Vision Science, Inc. (AVS), Securing Scalable Commercial IOL Supply and Accelerating Lens Portfolio Expansion Capability
- SpyGlass Pharma to Participate in Upcoming Investor Conferences
- Raymond James initiated coverage on SpyGlass Pharma with a new price target